# Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)

Study · id `cardio:ct-nct05774691` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05774691](<https://clinicaltrials.gov/study/NCT05774691>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05774691

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1000 participants.

## Technical summary

Registry record NCT05774691. Randomized; triple masking; primary purpose prevention. Start 2023-11-01 (actual); primary completion 2026-01-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1000 participants (enrolled count; ClinicalTrials.gov record NCT05774691, source copy `cardio:ctgov-nct05774691-2026-05-20`, retrieved 2026-10-26)
- Started: 2023-11-01 (actual) (ClinicalTrials.gov record NCT05774691, source copy `cardio:ctgov-nct05774691-2026-05-20`, retrieved 2026-10-26)
- Primary completion: 2026-01-02 (actual) (ClinicalTrials.gov record NCT05774691, source copy `cardio:ctgov-nct05774691-2026-05-20`, retrieved 2026-10-26)
- Completion: 2026-01-02 (actual) (ClinicalTrials.gov record NCT05774691, source copy `cardio:ctgov-nct05774691-2026-05-20`, retrieved 2026-10-26)
- Countries: Belgium; Netherlands (ClinicalTrials.gov record NCT05774691, source copy `cardio:ctgov-nct05774691-2026-05-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05774691-2026-05-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)
- Condition: Aortic Valve Stenosis
- Intervention (Drug): Protamine sulfate
- Intervention (Drug): Protamine sulfate
- Lead sponsor: St. Antonius Hospital
- Lead sponsor class: OTHER
- Collaborator: St. Antonius Research Fund
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: St. Antonius Hospital (`cardio:org-st-antonius-hospital`)

## Provenance

Content hash: f344fe6194b00626a688c1d60ba470a17e3ca7bf0809475f6404f08f90071291
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
